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BACKGROUND 
The World Health Organisation estimates that 2 billion people have been infected with hepatitis B and about 180 
million people infected with hepatitis C worldwide. More than 350 million have chronic hepatitis B and 130 million have 
chronic hepatitis C infection. Most infections of hepatitis B and C are from unsafe injection practices, both medical and 
nonmedical; from household contacts; or, in the case of hepatitis B, from ‘vertical’ transmission from mother to child. 
OBJECTIVE
This article discusses screening and management of hepatitis B and C in refugees who settle in Australia.
DISCUSSION 
Most people carrying hepatitis will be asymptomatic with infection detected by screening. Refugees need counselling, 
education and support to come to terms with the implications of hepatitis B and C for both themselves and their families. 
In Australia both viruses can be treated in those with active infection and general practitioners can be involved in 
diagnosis, follow up and shared care management.
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Narges aged 42 years, arrived in Australia with her four daughters after being detained in a detention 
centre for several months. Her husband Qadir, a journalist, left Afghanistan 5 years earlier and ended 
up in the USA. He has applied to be reunited with his family in Australia. Narges had escaped with the 
help of relatives after being badly beaten by the Taliban for showing her arm while shopping. She was 
afraid for the safety of herself and her daughters in Afghanistan and fled by sea with the help of people 
smugglers.
After appropriate pretest counselling you arrange blood tests for Narges and her family for hepatitis 
B virus (HBV) and hepatitis C virus (HCV). Blood tests show that Narges is HBV surface antibody (anti-
HBs) positive, HBV core antibody (anti-HBc) positive and HBV ‘envelope’ antibody (anti-HBe) positive. 
Her two eldest daughters have no HBV antigen or antibody detected. Her two younger daughters, aged 
10 and 12 years, are both HBV surface antigen (HBsAg) positive, anti-HBc positive and HBV ‘envelope’ 
antigen (HBeAg) positive. They both have normal alanine aminotransferase (ALT). Qadir has been found 
to be HCV antibody positive. Narges is concerned for the health of herself and her children and for the 
possibility of transmission of HBV and HCV within the family.
Narges probably contracted HBV between her second and third child. It was common in Afghanistan to 
have a tetanus injection with each pregnancy and this may have been the source of the infection. She has 
now cleared the virus and is immune but has passed it on perinatally to her two youngest children at a time 
when she was still HBsAg positive. Her two older girls do not have the infection and have no immunity. 
Because they are at risk of contracting the virus from their two younger sisters they will each need a course 
of hepatitis B vaccination. If Narges had been in Australia for the last two pregnancies the babies would 
have been given hepatitis B immune globulin (HBIG) and a course of hepatitis B vaccine neonatally. 
The two younger girls will need to be followed up every 6 months to watch the course of the disease. 
There is a possibility that they may clear the virus, but may eventually need treatment to stall the 
development of cirrhosis or hepatocellular carcinoma. Other family members will not need following up 
for HBV.
When Qadir arrives from the USA he will need to have a HCV qualitative polymerase chain reaction (PCR) 
to ascertain whether he has cleared the virus or whether it is still active and he is infectious. If the PCR is 
positive, a genotype should be done and he will need to be assessed by a specialist in viral hepatitis as to 
whether he qualifies for treatment with pegylated interferon and ribavirin. The possibility of Qadir passing 
HCV on to his family by razors, toothbrushes and any circumstance involving even small amounts of 
blood should be discussed. There is only a limited risk of contracting HCV during sexual intercourse and 
Narges and Qadir should be counselled in this regard. 
Health authorities will need to be notified about the children with active HBV and Qadir’s HCV.
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The World Health Organisation (WHO) 
estimates that 2 billion people have been 
infected with hepatitis B virus (HBV) 
worldwide with more than 350 million of 
these having chronic infection. Over 1 million 
people die each year from cirrhosis of the 
liver or hepatocellular carcinoma (HCC) 
caused by chronic HBV.1 Fifty-two percent 
of all cases of HCC are caused by HBV and 
92% of the world’s HBV related HCC is 
estimated to occur in developing countries.2 
Most infections throughout the world are 
‘vertical’ (ie. from mother to child), from 
household contacts, by sexual transmission, 
or from contact with unsterilised needles 
used by health professionals for treatment, 
immunisation or acupuncture.1 
	
Australia,	 like	most	 industrialised	 countries,	
has	a	predominantly	 ‘horizontal’	pattern	of	HBV	
transmission	where	 the	majority	 of	 infection	
is	 sexually	 acquired	 or	 through	 the	 sharing	 of	
injecting	drug	equipment.	The	hepatitis	B	vaccine	
has	 been	 available	 since	1982	 and	 in	 1991	 the	
WHO	 called	 for	 all	 children	 to	 be	 vaccinated	
against	 HBV.	 In	 2000,	 universal	 hepatitis	 B	
vaccination	was	 introduced	 into	Australia	with	





a	 rising	 prevalence	 of	 HCC.3	This	 increase	 in	
notifications	is	thought	to	be	due	to	the	increase	
in	migrants	 and	 refugees	 from	high	prevalence	
countries.	 A	 recent	 study	 in	 central	 Sydney	
(New	South	Wales)	 found	 that	 almost	 70%	of	
those	with	 chronic	HBV	were	 born	 overseas.3	
Screening	 of	 refugee	 populations	 is	 therefore	
important	(Table 1).
HBV and refugees to Australia




the	 poorest	 countries	 have	 not	 usually	 been	
vaccinated	 as	 governments	 cannot	 afford	 it	 or	
have	 chaotic	 infrastructure	 due	 to	war	 or	 civil	
unrest.	Ninety	percent	of	 those	 infected	 in	 the	
first	 year	of	 life	and	30–50%	of	 those	 infected	
from	 1–4	 years	 of	 age	will	 go	 on	 to	 develop	
chronic	 infection.	These	 children	 have	 a	 25%	
risk	of	dying	of	the	sequelae	of	their	HBV.1
	 The	 greatest	 risk	 of	 HBV	 infection	 in	
refugee	 populations	 is	 in	 those	 children	 of	
infected	mothers	 (Table 2).	 Other	 high	 risk	
groups	 include:	 those	who	 have	 had	medical	
procedures	 such	 as	 injections,	 as	 part	 of	 an	
immunisation	 program,	with	 childbirth	 or	 as	 a	
preferred	 treatment	 for	 common	 illnesses;4	 or	
circumcision,	which	is	becoming	more	common	
in	 parts	 of	Africa	 as	 it	 is	 thought	 to	 decrease	
the	 transmission	of	HIV.5	Hepatitis	B	 increases	
with	age	and	is	also	more	common	in	men.	The	
risk	 of	HBV,	 as	with	 all	 infectious	 diseases,	 is	
increased	 in	 the	 country	 of	 origin	 of	 refugees	
because	 of	 poor	 nutrition,	 crowded	 conditions	
and	lack	of	health	facilities.6	
Immunological stages and 
transmissibility 





Table 1. Reasons for screening for HBV6 
• Counselling about ways to reduce HBV transmission 
• Vaccination of close contacts, sexual partners and household 
• Infants born to HBsAg positive women need vaccine and immune globulin 
• Risk for progression to cirrhosis and hepatocellular carcinoma
• Eligibility for treatment
•  Educating patients on medical and social consequences of infection including public 
health notifications
Table 2. Prevalence of hepatitis B1
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Parts of Middle East
8–20 70–95 Mostly vertical
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Hepatitis	B	core	IgM	will	develop	in	recognition	
of	 the	 presence	 of	 HBV,	 but	 this	 immune	
response	 is	 not	 sufficient	 to	 eliminate	 the	
virus.	This	 stage	 of	 immune	 tolerance	 can	 last	
several	 decades	 in	 those	who	 contracted	HBV	
‘vertically’	 but	 only	 2–4	weeks	 in	 those	who	
contracted	HBV	‘horizontally’	as	adults.7	
	 In	the	second	stage	there	is:	
•	an	 immunologic	 response	 with	 the	
development	of	HBV	antibodies	
•	hepatitis	B	viral	levels	decline,	but
•	often	 ‘flares’	 of	 hepatitis	with	 increases	 in	
alanine	 aminotransferase	 (ALT)	 levels	 as	
the	 body	 attempts	 to	 rid	 itself	 of	 infected	
hepatocytes.	
There	 is	 an	 increased	 likelihood	of	 progressive	
disease	 in	 those	 who	 have	 more	 frequent	
flares	or	 in	 those	whom	 this	phase	persists	 for	
a	 prolonged	 period	 (weeks	 to	 years).7	 People	
who	are	immunosuppressed	may	have	high	viral	
loads	but	no	illness	as	it	is	the	immune	response	
that	 causes	 the	 destruction	 of	 liver	 cells	 and	
‘flares’.	 If	 the	 immunosuppression	 improves,	
patients	who	 are	 chronic	 carriers	may	 develop	
severe	hepatitis.	
	 In	the	third	phase,	the	body	has	cleared	most	
of	 the	 virus	 and	 the	ALT	may	 return	 to	normal.	







This	 has	 been	described	 as	 an	 ‘inactive	 carrier	
state’	but	the	patient	remains	infectious	and	HBV	
can	be	 reactivated	either	 spontaneously	or	 as	 a	
result	of	immunosuppression.8
	 The	presence	of	maternal	HBeAg	 increases	
the	 risk	 of	 perinatal	 transmission	 of	 HBV	 to	
the	 infant	 (10–40%	 risk	 to	 infants	 of	 HBeAg	
negative	mothers	vs.	79–90%	risk	 to	 infants	of	
HBeAg	 positive	mothers).7	 Ninety	 percent	 of	
those	with	 vertically	 transmitted	HBV	 remain	
HbsAg	 positive9	 and	 rarely	 convert	 to	HBeAg	
negative	and	anti-HBe	positive.
Blood tests and what they mean
The	 interpretation	 of	 blood	 tests	 for	 HBV	 is	
confusing,	 but	 for	 general	 practit ioners	
screening	 refugees	 for	HBV	 it	 is	 important	 to	
have	 some	 understanding	 of	 their	 meaning	
so	 as	 to	 decide	 on	 prevention,	 follow	 up	 and	
treatment	 options.	Table 3	 and	4	 describe	 the	
various	tests	and	their	interpretation.









should	 be	 done	 to	 guide	 further	management.	
The	 presence	 of	HBeAg	 indicates	 a	 high	 viral	
load	 and	often	 there	will	 be	 active	 hepatitis.	 It	
is	not	found	in	people	who	are	HBsAg	negative.	
Those	 who	 are	 HBeAg	 positive	 therefore	
require	more	 regular	monitoring	 of	 their	 liver	
function.	A	person	who	 is	HBsAg	positive	 and	





assessment.8	 Because	 of	 the	 current	 cost	 of	
this	 test	 it	 needs	 to	 be	 done	 in	 the	 hospital	
environment.	 However,	 in	 the	 near	 future	
hepatitis	B	DNA	assays	will	be	publicly	 funded	
for	 pretreatment	 and	monitoring	 of	 patients	
with	chronic	HBV.
	 Those	 who	 are	 HBsAg	 positive	 have	 a	
5	 year	 cumulative	 incidence	 of	 progression	
to	 cirrhosis	 of	 8–20%.	Without	 treatment,	
cirrhosis	 can	 cause	 ascites,	 jaundice,	 bleeding	
and	 hepatic	 encephalopathy	with	 only	 a	 71%	
survival	rate	at	5	years	(Table 5).9	
	 Screening	 for	 HCC	 by	 ultrasound	 and	
Table 3. Definitions for hepatitis B1,24 
Hepatitis B virus (HBV): is a hepadnavirus, 42 nm partially double stranded DNA composed of a 27 nm nucleocapsid core (HBcAg) 
surrounded by an outer lipoprotein coat (also called envelope) containing the surface antigen (HBsAg). HBV is present in blood, 
saliva, semen, vaginal secretions and menstrual blood of infected individuals
Hepatitis B surface antigen (HBsAg): a serologic marker on the surface of HBV. It can be detected in high levels in serum during 
acute or chronic hepatitis. The presence of HBsAg indicates that the person is infectious. The body usually produces antibodies to 
HBsAg as part of the normal immune response to infection 
Hepatitis B surface antibody (anti-HBs): also abbreviated as HBsAb. The presence of anti-HBs is generally interpreted as indicating 
recovery and immunity from HBV infection. Anti-HBs also develops in a person who has been successfully vaccinated against HBV 
Total hepatitis B core antibody (anti-HBc): also abbreviated as HBcAb. Appears at the onset of symptoms in acute hepatitis B and 
persists for life. The presence of anti-HBc indicates previous or ongoing infection with HBV in an undefined time frame 
Hepatitis B 'envelope' antigen (HBeAg): a secreted product of the nucleocapsid gene of HBV found in serum during acute and 
chronic HBV. Its presence indicates the virus is replicating and the infected individual has high levels of HBV 
Hepatitis B 'envelope' antibody (anti-HBe): also abbreviated as HBeAb. Produced by the immune system temporarily during acute 
HBV infection or consistently during or after a burst in viral replication. Spontaneous conversion from e antigen to e antibody 
(a change known as seroconversion) is a predictor of long term clearance of HBV in patients undergoing antiviral therapy and 
indicates lower levels of HBV 
Hepatitis B immune globulin (HBIG): a product available for prophylaxis against HBV infection. HBIG is prepared from plasma 
containing high titres of HBsAb and provides short term protection (3–6 months)
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α-fetoprotein	 should	 be	 done	 in	 patients	
who	 are	 chronically	 infected,	 in	 particular	
those	 at	 high	 risk	 (eg.	men	 aged	 >45	 years,	
those	with	 cirrhosis,	 and	 those	with	 a	 family	
history).	Hepatocellular	 carcinoma	 arises	most	
commonly	 in	 patients	with	 cirrhosis	 but	 can	
also	occur	with	only	minimal	signs	of	other	liver	
damage.9	A	male	 child	 infected	 at	 birth	 has	 a	
25–40%	 lifelong	 risk	 of	 developing	 cirrhosis	
or	 HCC.7	Therefore	 GPs	 need	 to	 continue	 to	
follow	up	those	who	are	HBsAg	positive	looking	
for	 both	 evidence	 of	 cirrhosis	 and	 of	HCC.	An	
online	 algorithm	 to	help	with	 screening	 can	be	
accessed	 at	 http://clinicaloptions.com/hepatitis/
management%20series/chronic%20care.aspx.
Co-infection with hepatitis D
The	hepatitis	D	 virus	 (HDV)	 is	 a	 defective	 virus	
whose	outer	 coat	 is	 derived	 from	HBV	surface	
antigen.	Hence	 it	 needs	 the	HBV	 to	 exist	 and	
is	 transmitted	by	 the	 same	 routes.	Hepatitis	D	
virus	 can	 be	 acquired	 either	 as	 a	 co-infection	
(occurs	 simultaneously)	 with	 HBV	 or	 as	 a	
superinfection	 in	 those	with	 existing	 chronic	
HBV	infection.	Hepatitis	D	antigen	and	antibody	
should	be	 requested	where	 liver	 function	 tests	
are	 persistently	 elevated	 in	 a	 person	who	 is	
HBsAg	 positive	 but	 has	 a	 low	 viral	 load	 and	
no	 other	 comorbid	 risk	 factors.	 HBV-HDV	 co-
infection	may	have	more	 severe	 acute	 disease	
and	 a	 higher	 risk	 (2–20%)	 of	 developing	 acute	
liver	 failure	 compared	with	 those	 infected	with	
HBV	 alone.	 Chronic	HBV	 carriers	who	 acquire	
HDV	 superinfection	 usually	 develop	 chronic	
HDV	 infection	 and	 have	 an	 increased	 risk	 of	
progression	to	cirrhosis.10
Treatment 
Treatment	 for	HBV	will	 take	place	 after	 referral	
to	a	specialised	unit,	 and	 liver	biopsy	 for	 those	
with	 abnormal	ALT	 levels	 and	 a	 high	 viral	 load.	
Success	is	defined	as:	
•	 loss	of	HBeAg	
•	elimination	 of	 detectable	 HBV	 from	 the	
blood,	and	
•	normalisation	of	liver	function	tests.9	
Lamivudine,	 entecavir	 and	 adefovir	 are	
nucleoside	 analogues	 that	 have	 conventionally	
been	 used	 in	 the	 treatment	 of	HBV.	They	 are	
well	 tolerated	 and	 have	 few	 side	 effects	with	
a	 seroconversion	 rate	 from	HBeAg	 positive	 to	
HBeAg	negative	 of	 73%	at	 4	 years.9	 Problems	
include	the	development	of	drug	resistance	and	
the	 low	 rates	 of	 sustained	 seroconversion.11	
Weekly	 subcutaneous	pegylated	 interferon	has	
recently	 been	 approved	 for	 use	 in	 those	with	
liver	 biopsy	 signs	 of	 cirrhosis	 and/or	 fibrosis	
with	 a	 success	 rate	 of	 40%	 after	 a	 6	month	
course.9	 Early	 diagnosis	 of	 HCC	 allows	 for	







   
















































*  Might be: recovering from acute HBV infection, distantly immune and test not sensitive enough 
to detect very low level of anti-HBs in serum, susceptible with a false positive anti-HBc, or 
undetectable level of HBsAg present in the serum and the person is actually chronically infected 
Figure 1. Screening and monitoring algorithm for hepatitis B8 
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treatment	by	transplantation,	ablation,	resection,	
hemihepatectomy,	 intra-arterial	 chemotherapy,	
embolisation	 or	 percutaneous	 intralesional	
ethanol	injection.9	
Hepatitis C
The	WHO	 estimates	 that	 about	 180	million	
people	 have	 been	 infected	with	 hepatitis	 C	
(HCV)	 and	 about	 130	million	 still	 have	 chronic	
infection.	 It	has	estimated	that	3–4	million	new	
infections	occur	each	year.12
	 In	 Egypt,	where	many	 Sudanese	 refugees	
stay	 before	 they	 come	 to	 Australia,	 the	
prevalence	 of	 HCV	 antibodies	 is	 15–20%.13	
Prevalence	 of	HCV	 antibodies	 is	 5%	 in	 young	
sexually	 active	 adults	 in	 the	 Central	 African	
Republic14	 and	 3%	 and	 8%	 respectively	 in	
migrants	to	Australia	from	Laos	and	Cambodia.15	






infects	 humans.	 Processes	 that	move	 blood	
from	 one	 person	 to	 another	 transmit	 it.	The	
major	 risk	 factor	 for	 transmission	 is	 exposure	
to	 contaminated	 needles	 and	 syringes.	This	
may	 occur	 due	 to	medical,	 surgical	 or	 dental	
treatment	 particularly	 in	 resource	poor	 settings	
or	 in	 the	 context	 of	 injecting	 drug	 use.17	The	
risk	 of	mother	 to	 child	 transmission	 is	 around	
5%.	The	factors	that	put	someone	at	 increased	
risk	 of	 HCV	may	 also	 increase	 their	 risk	 of	
contracting	HIV.	
	 Sexual	 transmission	 is	 possible	 although	
rare,	 and	 can	 occur	 if	 blood	 is	 present	 during	
sex,	particularly	 in	the	presence	of	genital	ulcer	




Hepatitis	 C	 virus	 is	 cleared	 by	 the	 immune	
system	in	about	30%	of	people	infected.19	If	HCV	
is	cleared,	the	antibody	remains	 in	most	people	
but	 the	 virus	 is	 not	 detected	 by	 polymerase	
chain	 reaction	 (PCR).	There	 is	 no	 ongoing	 liver	




	 When	 someone	 is	 identified	 as	 HCV	










immune	 complex	 deposition	 and	 autoimmune	
stimulation	but	occurs	slowly	over	many	years.
	 Liver	 injury	 is	 rated	 on	 the	 degree	 of	
fibrosis	 and	 continuing	 activity.20	 Cirrhosis,	
decompensation	 and	 HCC	 are	 possible	 liver	
related	 disease	 outcomes	 after	many	 years	 of	
infection	 (Table 5).	 Ongoing	 liver	 damage	 is	
more	 common	 in	 people	with	 abnormal	 liver	
function	 tests	 (LFTs)	 but	 also	 occurs	 in	 about	
20%	of	people	with	normal	LFTs.20
Treatment 
Treatment	 is	 available	 and	 should	be	discussed	
with	 all	 patients	 who	 have	 a	 positive	 PCR	
(Figure 2).	Treatment	is	with	pegylated	interferon	
and	 ribavirin.21	Treatment	 outcome	 depends	
on	 genotype.	 In	Australia,	 the	most	 common	
genotypes	 are	 1	 and	 3.22	 Genotypes	 3	 and	 2	
require	6	months	 treatment	with	~80%	chance	
of	 clearing	 the	 virus	 (sustained	 viral	 response	
[SVR]).	Genotypes	 1	 and	 4	 require	 12	months	
treatment	and	have	SVR	of	about	50%.	Response	
rates	are	decreased	if	cirrhosis	is	present.
	 Some	 people	 progress	 through	 treatment	
without	difficulty.	However,	most	will	experience	
side	 effects	 including	 flu-like	 symptoms,	
i rr i tabi l i ty, 	 insomnia, 	 anorexia, 	 nausea,	
vomiting,	 rash,	myalgia,	 arthralgia,	 depression	
and	 psychosis.23	 Bone	 marrow	 depression	
can	 lead	 to	 anaemia,	 thrombocytopaenia	 and	
leukopaenia.	Treatment	 can	 also	 precipitate	
thyroid	dysfunction.
	 Treatment	may	 aggravate	 existing	 diabetes,	
epilepsy,	 psoriasis,	 depression	 and	 psychosis.	
Patients	must	 be	 adequately	 advised,	 and	 if	
there	 is	 a	 history	 of	 depression	 or	 psychosis,	
assessed	 by	 a	 psychiatrist	 experienced	 in	
managing	 people	 being	 treated	with	 interferon	
before	commencing	treatment.
	 Treatment	 can	 only	 be	 undertaken	 once	
within	 the	Australian	 Pharmaceutical	 Benefits	
Scheme	 (PBS).	 If	 a	 person	 withdraws	 from	
treatment	 or	 their	 virus	 is	 resistant,	 pegylated	




A	pretest	 discussion	 to	 gain	 informed	 consent	
should	 be	 done	with	 an	 accredited	 interpreter.	
It	might	 include	 the	 following:	 ‘there	 are	 some	
illnesses	 that	might	 have	 only	minimal	 or	 no	
symptoms	but	which	can	still	be	 important	and	
are	 often	 successfully	 treated	 in	Australia.	This	
includes	 syphilis,	 schistosomiasis,	 hepatitis	 B,	
hepatitis	C	and	HIV.	We	test	for	these	 illnesses	
so	 we	 can	 try	 to	 protect	 people	 from	 their	
Table 5. Clinical evidence of cirrhosis25
• Subtle features include:
 – lethargy
 – right upper quadrant discomfort
 – hard liver edge
 – splenomegaly
 – blood tests
 – slightly low serum albumin
 – slightly prolonged INR




• May be asymptomatic
•  Skin rash, palpable purpura on lower 
limbs, proteinuria
• More significant features
 – ascites
 – muscle wasting
 – hepatic encephalopathy
 –  upper gastrointestinal bleeding from 
oesophageal or gastric varices
 – hypersplenism
• Thrombocytopaenia, leukopaenia
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effects	if	left	untreated	and	help	protect	the	rest	
of	 the	 family	 from	catching	 them.	Some	of	 the	
illnesses	are	contagious	and	we	need	to	tell	the	
appropriate	health	worker	at	 the	department	of	
health	 if	you	have	them	as	they	 like	 to	be	sure	
that	we	are	looking	after	you	and	your	family.	If	
you’re	uncomfortable	about	having	any	of	these	
tests	 now	 and	would	 like	 to	 think	 about	 it	 or	
discuss	it	further	with	the	doctor	or	your	family,	
we	can	talk	about	it	again	later’.
	 For	many	 refugee	 patients,	 the	 only	 blood	
borne	 virus	 they	 have	 known	 is	HIV	 and	 they	
may	 be	 confused	 about	 the	 implications	 and	
significance	 of	 HBV	 or	 HCV.	The	 diagnosis	
of	 a	 potentially	 serious	 illness	with	 difficult	
treatment	 will	 be	 added	 to	 other	 stressors	
such	 as	 a	 new	 country,	 a	 strange	 health	
system,	 limited	 support	 and	 the	 fear	 of	
transmission.	A	good	understanding	about	HBV	
and	 HCV,	 thoroughly	 explained	with	 the	 aid	
of	 an	 accredited	 interpreter,	 is	 of	 the	 utmost	
importance	 at	 all	 stages	 through	 screening,	
vaccination,	 notification	 to	 health	 authorities,	
follow	 up	 and	 treatment.	Many	 states	 have	




with	 a	 higher	 prevalence	 of	HBV	 and	HCV,	 all	
GPs	will	need	to	be	aware	of	the	latest	screening	
and	 treatment	protocols.	Refugees	often	come	
to	Australia	 from	 countries	with	 limited	 health	
care	 facilities	 and	may	 be	 asymptomatic	 and	
unaware	 that	 they	 are	 carrying	 these	 blood	
borne	 viruses.	The	 diagnosis,	 treatment	 and	
prognosis	 of	 hepatitis	 depends	 on	 appropriate	
screening,	immunisation,	follow	up	and	referral.	
For	 people	 such	 as	 Qadir,	 Narges	 and	 their	
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Table 6. Support services 
Australian Hepatitis Council 
Tel 02 6232 4257
Fax 02 6232 4318 
Email info@hepatitisaustralia.com 
www.hepatitisaustralia.com
Australian Capital Territory 
Tel 02 6257 2911
Fax 02 6257 1611
Email info@acthepc.org
www.acthepc.org 
New South Wales 
Tel 02 9332 1599
1800 803 990 (country) 




NT AIDS and Hepatitis Council
Tel 08 8941 1711
1800 880 899 (free call line) 




Tel 07 3236 0610
1800 648 491 (country) 




Tel 08 8362 8443
1800 021 133 (country)
Fax 08 8362 8559
Email admin@hepccouncilsa.asn.au
www.hepccouncilsa.asn.au
Tasmanian Council on AIDS, Hepatitis and 
Related Diseases 
Tel 03 6234 1242
1800 005 900 (country) 




Tel 03 9380 4644 
1800 703 003 (country)




Information line 08 9328 8538 
Tel 08 9227 9800 





PEACE Multicultural HIV and Hepatitis 
Services
Tel 08 8245 8100
Mobile 0418 824739
Email e.oudih@rasa.org.au 
Multicultural HIV/AIDS & Hepatitis C 
Service
Tel 02 9515 5030 
Fax 02 9550 6815
www. multiculturalhivhepc.net.au 
Multicultural Health & Support Service 
Tel 03 9342 9721 
Fax 03 9342 9799 
Mobile 0400 075983
Email naomin@nrchc.com.au
CORRESPONDENCE email: afp@racgp.org.au
